Tourmaline Bio, Inc. Common Stock (TRML)
Tourmaline Bio, Inc. is a biotechnology company focused on discovering and developing novel therapeutics for autoimmune, inflammatory, and neurodegenerative diseases. It leverages its proprietary platform to identify small molecules that modulate specific biological pathways, aiming to deliver targeted treatments with improved safety profiles.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 20, 2023 | $1.51 | 2023-10-20 | 2023-10-16 |
Dividends Summary
- Tourmaline Bio, Inc. Common Stock has issued 1 dividend payments over the past 0 years
- The most recent dividend was paid 733 days ago, on October 20, 2023
- The highest dividend payed out to investors during this period was $1.51 per share
- The average dividend paid during this period was $1.51 per share.
Company News
Over 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.
Law firm Monteverde & Associates is investigating the proposed sale of Tourmaline Bio to Novartis, where shareholders will receive $48.00 per share, to determine if the transaction is fair.
Tourmaline Bio, Inc. (TRML) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.